Ultralife Corporation ULBI
6.16
0.26
4.41%
as of 25 Sep
- Market cap
- $100.8M
- P/E
- 0.0×
Follow ULBI
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 68.20 |
+8 more quarters Free account |
P/S ratio |
0.56 | 0.58 | 0.50 | 0.61 | |
P/FCF ratio |
51.84 | 17.71 | 13.37 | 12.68 | |
P/Operating CF |
88.62 | 48.14 | 63.93 | 573.36 | |
P/B ratio |
0.79 | 0.84 | 0.73 | 0.83 | |
Price to Tangible BV |
1.37 | 1.47 | 1.29 | 1.65 | |
EV/Sales |
0.76 | 0.78 | 0.71 | 0.83 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 13.10 | |
EV/Operating CF |
27.91 | 14.92 | 12.33 | 12.32 | |
EV/FCF |
70.52 | 24.03 | 19.04 | 17.27 | |
Quick Ratio |
1.11 | 1.01 | 1.16 | 1.19 | |
Current Ratio |
2.87 | 2.56 | 2.83 | 2.99 | |
Net Debt/EBITDA |
7.86 | 33.05 | (4.37) | 76.85 | |
Debt/Assets |
20.64% | 21.59% | 22.89% | 22.63% | |
Debt/Equity |
0.34 | 0.37 | 0.38 | 0.37 | |
Asset Turnover |
0.86 | 0.85 | 0.87 | 0.95 | |
Operating CF/Net income |
0.47 | (5.00) | (0.20) | (0.16) | |
Capex/Depreciation |
(0.33) | (0.56) | (0.64) | (0.67) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
6.73% | 6.24% | 5.82% | 6.58% | |
Selling, General and Administrative Expense of Revenue |
15.03% | 15.52% | 15.80% | 17.79% | |
Intangible Assets out of Total Assets |
0.26 | 0.25 | 0.26 | 0.31 | |
Share Based Compensation of Revenue |
0.19% | 0.00% | 0.49% | 0.54% | |
Graham Net Nets |
0.22 | 0.18 | 0.20 | 0.14 | |
Graham Number |
0.00 | 0.00 | 0.00 | 4.31 | |
Earnings Yield |
(6.33%) | (7.67%) | (6.29%) | 1.47% | |
Free Cash Flow Yield |
1.93% | 5.65% | 7.48% | 7.88% | |
Revenue per Share |
2.88 | 2.85 | 2.91 | 2.61 | |
Operating CF per Share |
0.07 | 0.14 | 0.09 | 0.01 | |
Capex per Share |
(0.03) | (0.05) | (0.05) | (0.06) | |
Free Cash Flow per Share |
0.04 | 0.09 | 0.04 | (0.05) | |
Cash per Share |
0.40 | 0.53 | 0.56 | 0.56 | |
Shareholders Equity per Share |
7.96 | 7.79 | 7.82 | 8.26 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.96 | 7.79 | 7.82 | 8.26 | |
Free Cash Flow |
0.74 | 1.49 | 0.61 | (0.80) | |
Working Capital |
69.80 | 67.05 | 68.47 | 66.92 | |
Capital Expenditures |
(0.45) | (0.77) | (0.88) | (0.99) | |
Net Current Asset Value |
23.60 | 19.22 | 19.02 | 15.81 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 25.02 | |
Capex to Sales |
0.01 | 0.02 | 0.02 | 0.02 | |
Net Profit Margin |
5.30% | (0.95%) | (15.31%) | (2.81%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 18.38 | |
| Other line items | |||||
Average Receivables |
33.55 | 35.24 | 31.66 | 29.34 | |
Average Payables |
18.82 | 20.34 | 15.79 | 13.42 | |
Average Inventory |
54.66 | 52.57 | 52.69 | 48.37 | |
Average Assets |
218.56 | 222.19 | 218.68 | 197.34 | |
Average Common Equity |
135.62 | 133.17 | 132.16 | 136.03 |
Columns are period end dates